Table 3.

The development status of TLR antagonists/inhibitors: class of antibodies.

Compound	Target	Indication	Status	Company	References
OPN-305	TLR2	Delayed graft function	Phase II	Opsona therapeutics	Arslan et al., 2012; Reilly et al., 2013
T2.5	TLR2	Septic shock, cardiac fibrosis, cerebrovascular ischemia	Animal study	–	Meng et al., 2004; Spiller et al., 2008; Ziegler et al., 2011; Wang et al., 2014
NI-0101	TLR4	RA	Phase I	NovImmune	Monnet et al., 2015, 2017
1A6	TLR4/MD2	Sepsis	Experimental	–	Spiller et al., 2008; Lima et al., 2015

RA, rheumatoid arthritis.